N/A N=62 UltraShape Power for Abdominal Fat and Circumference Reduction
Excess Abdominal Fat
Primary: Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound — -10.5 percentage change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=85 Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Primary Progressive Multiple Sclerosis
Primary: Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase — -0.13; -1.04 units on a…
Phase 2 N=93 A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Number of Participants With Adverse Events (AEs) — 6; 55; 30; 5 Participants
N/A N=210 Spectrophon LTD Glucometry Monitor Accuracy
Glucose Metabolism Disorders · Diabetes Mellitus
Primary: Percentage of Measurements With < 15% Error — 95.25; 100; 94.5; 100 Percentage of measures with error <15%
Phase 1 N=30 The Effects of LY2409021 on the Liver
Diabetes Mellitus, Type 2
Primary: Change From Baseline to Day 28 in Liver Fat Average Percent (%) — -0.47; 5.55; -1.49; 4.45 percentage of liver fat average
N/A N=51 Shared Decision Making for Prescription Opioids After Cesarean Delivery
Pregnancy · Cesarean Section · Prescriptions
Primary: Pain Management and Opioid Usage Measured by Telephone Questionnaire — 20.0; 20.0; 15.5; 4.0 number of oxycodone 5mg tablets — p=<0.001
Phase 4 N=30 Pain Expectations in Subjects With Osteoarthritis
Osteoarthritis
Primary: Resting Pupil Diameter — 64; 72; 69; 66.9 mm — p=0.540
Phase 3 N=43 A Study of Galunisertib in Participants With Myelodysplastic Syndromes
Myelodysplastic Syndromes
Primary: Percentage of Participants With Hematological Improvement (HI) — 31.7; 0.0 percentage of participants
Phase 2 N=85 Vitamin D HIV Study on Postmenopausal Women
HIV
Primary: Change in Bone Mineral Density (BMD) — 0.4; -0.8 percentage change
Phase 3 N=182 Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
Anesthesia, General
Primary: Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium — 3.28; 55.50…
N/A N=118 The Outcomes of Proximal Humerus Fractures in Children
Humeral Fractures
Primary: Number of Participants With Indicated Status as Assessed by Mail Questionnaire Upper Extremities Functional Index (UEFI) — 4; 4; 24 Participants
Phase 1 N=35 A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study
Dysentery, Bacillary
Primary: Concentrations of Immunoglobulin (IgG) Against Lipopolysaccharide (LPS) S. Sonnei O-antigen — 168; 5.17; 38 EU/mL
Phase 1 N=16 A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Administration of GSK2838232 Tablet…
N/A N=22 Diabetes and Gastric By- Pass
Type 2 Diabetes
Primary: Response in Glucose AUC at Baseline vs. Following Gastric Bypass Surgery — 61647.0; 59476.1 mg/dL*min
N/A N=594 Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients
Tuberculosis · Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Primary: Number of Participants With Treatment-Related Adverse Events — 387; 113 Participants